217 related articles for article (PubMed ID: 12907611)
41. Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: role of sulfotransferase induction.
Davis W; Hewer A; Rajkowski KM; Meinl W; Glatt H; Phillips DH
Cancer Res; 2000 Jun; 60(11):2887-91. PubMed ID: 10850433
[TBL] [Abstract][Full Text] [Related]
42. Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxytamoxifen.
Dasaradhi L; Shibutani S
Chem Res Toxicol; 1997 Feb; 10(2):189-96. PubMed ID: 9049430
[TBL] [Abstract][Full Text] [Related]
43. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the DNA damaging potential of cannabis cigarette smoke by the determination of acetaldehyde derived N2-ethyl-2'-deoxyguanosine adducts.
Singh R; Sandhu J; Kaur B; Juren T; Steward WP; Segerbäck D; Farmer PB
Chem Res Toxicol; 2009 Jun; 22(6):1181-8. PubMed ID: 19449825
[TBL] [Abstract][Full Text] [Related]
45. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen.
Osborne MR; Hewer A; Hardcastle IR; Carmichael PL; Phillips DH
Cancer Res; 1996 Jan; 56(1):66-71. PubMed ID: 8548777
[TBL] [Abstract][Full Text] [Related]
46. Characterization of the major DNA adducts in the liver of rats chronically exposed to tamoxifen for 18 months.
Firozi PF; Vulimiri SV; Rajaniemi H; Hemminki K; Dragan Y; Pitot HC; DiGiovanni J; Zhu YH; Li D
Chem Biol Interact; 2000 Apr; 126(1):33-43. PubMed ID: 10826652
[TBL] [Abstract][Full Text] [Related]
47. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen.
Pongracz K; Pathak DN; Nakamura T; Burlingame AL; Bodell WJ
Cancer Res; 1995 Jul; 55(14):3012-5. PubMed ID: 7606720
[TBL] [Abstract][Full Text] [Related]
48. Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues.
Brown K; Brown JE; Martin EA; Smith LL; White IN
Chem Res Toxicol; 1998 May; 11(5):527-34. PubMed ID: 9585484
[TBL] [Abstract][Full Text] [Related]
49. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers.
Kim SY; Laxmi YR; Suzuki N; Ogura K; Watabe T; Duffel MW; Shibutani S
Drug Metab Dispos; 2005 Nov; 33(11):1673-8. PubMed ID: 16099924
[TBL] [Abstract][Full Text] [Related]
50. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.
Pathak DN; Pongracz K; Bodell WJ
Carcinogenesis; 1995 Jan; 16(1):11-5. PubMed ID: 7834794
[TBL] [Abstract][Full Text] [Related]
51. The DNA-damaging potential of tamoxifen in breast cancer and normal cells.
Wozniak K; Kolacinska A; Blasinska-Morawiec M; Morawiec-Bajda A; Morawiec Z; Zadrozny M; Blasiak J
Arch Toxicol; 2007 Jul; 81(7):519-27. PubMed ID: 17593413
[TBL] [Abstract][Full Text] [Related]
52. Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts.
Shibutani S; Dasaradhi L; Terashima I; Banoglu E; Duffel MW
Cancer Res; 1998 Feb; 58(4):647-53. PubMed ID: 9485016
[TBL] [Abstract][Full Text] [Related]
53. Stereoselective metabolic activation of alpha-hydroxy-N-desmethyltamoxifen: the R-isomer forms more DNA adducts in rat liver cells.
Osborne MR; Hewer A; Phillips DH
Chem Res Toxicol; 2004 May; 17(5):697-701. PubMed ID: 15144227
[TBL] [Abstract][Full Text] [Related]
54. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients.
Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM
Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226
[TBL] [Abstract][Full Text] [Related]
55. Analysis of tamoxifen-DNA adducts in endometrial explants by MS and 32P-postlabeling.
Beland FA; Churchwell MI; Hewer A; Phillips DH; Gamboa da Costa G; Marques MM
Biochem Biophys Res Commun; 2004 Jul; 320(2):297-302. PubMed ID: 15219826
[TBL] [Abstract][Full Text] [Related]
56. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen.
Martin EA; Rich KJ; White IN; Woods KL; Powles TJ; Smith LL
Carcinogenesis; 1995 Jul; 16(7):1651-4. PubMed ID: 7614701
[TBL] [Abstract][Full Text] [Related]
57. Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system.
Shibutani S; Reardon JT; Suzuki N; Sancar A
Cancer Res; 2000 May; 60(10):2607-10. PubMed ID: 10825130
[TBL] [Abstract][Full Text] [Related]
58. Glutathione depletion enhances the formation of endogenous cyclic DNA adducts derived from t-4-hydroxy-2-nonenal in rat liver.
Chung FL; Komninou D; Zhang L; Nath R; Pan J; Amin S; Richie J
Chem Res Toxicol; 2005 Jan; 18(1):24-7. PubMed ID: 15651845
[TBL] [Abstract][Full Text] [Related]
59. Ultra-performance liquid chromatography-tandem mass spectrometry for rapid and highly sensitive analysis of stereoisomers of benzo[a]pyrene diol epoxide-DNA adducts.
Feng F; Wang X; Yuan H; Wang H
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):2104-12. PubMed ID: 19535305
[TBL] [Abstract][Full Text] [Related]
60. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
